Am J Trop Med Hyg. 2026 Feb 24:tpmd250662. doi: 10.4269/ajtmh.25-0662. Online ahead of print.
ABSTRACT
Rheumatic manifestations are the third most common clinical features of Hansen’s disease (HD), after cutaneous and neurological involvement. However, few studies have systematically characterized these manifestations, and most lack appropriate controls and standardized assessments. To address this gap, the present cross-sectional study was conducted to evaluate the rheumatic manifestations associated with HD. The study included 23 patients with HD and 23 age- and sex-matched non-HD controls from Puerto Rico. All participants underwent a standardized evaluation and examination for rheumatic features. Demographic data, clinical manifestations, comorbidities, and pharmacologic treatments were documented. Statistical analyses were performed using bivariate methods. The mean (SD) age of HD patients was 51.3 (15.7) years, and 60.8% were female. Regarding treatment status, 8.7% had received <1 year of multidrug therapy (MDT), 8.7% had received at least 1 year of MDT, and 82.6% had completed therapy. Overall, 87% of HD patients presented with rheumatic manifestations, most commonly arthralgia (73.9%) and arthritis (69.6%). Compared with controls, HD patients exhibited a significantly higher proportion of arthritis, particularly involving the small joints of the hands, as well as tendinopathy, dactylitis, and swollen hand and foot syndrome. These manifestations were significantly associated with leprosy reactions and multibacillary disease. In conclusion, rheumatic manifestations were present in 87% of HD patients, with several being significantly more frequent than in controls. Moreover, a substantial proportion of patients continued to experience persistent rheumatic manifestations despite receiving or completing MDT. Given their potential to substantially impair functional status, these manifestations should be recognized early to ensure timely and appropriate management.
PMID:41734397 | DOI:10.4269/ajtmh.25-0662
